Sumitomo Dainippon Pharma will sign an agreement on the use of Datavant`s services (which has platform technology for de-identification and interconnection of external health data to facilitate their analysis) and Alyvant (which has a real-time marketing platform for real-time sales optimization) which are the two Vants health technologies that will remain subsidiaries of Roi. These agreements should enable sumitomo Dainippon Pharma to maximize the value of its product portfolio. The memorandum is not legally binding, with the exception of certain provisions. The two companies will continue to carry out due diligence and, if necessary, conduct reciprocal consultations as they work to conclude a final legally binding agreement on detailed conditions, etc., of the Strategic Alliance by the end of October 2019. The Company`s forward-looking statements are based on management`s current expectations and beliefs and are subject to a number of risks and uncertainties that may result in actual results significantly different from expected, anticipated or expected results. While the Company considers the assumptions underlying these forward-looking statements to be appropriate, they are not guaranteed and the Company cannot provide assurance that its expectations will be met. However, factors that could have a significant impact on the company`s business and future prospects or that could lead to actual results being materially different from expectations are not limited to: the possibility that Roivant and Sumitomo Dainippon Pharma will not be able to reach a definitive agreement on the terms or date specified in this press release; the possibility that Roivant and Sumitomo Dainippon Pharma may not be able to obtain the necessary regulatory approvals or that other conditions for the conclusion of the transaction will not be met, so that the transaction is not concluded or the conclusion may be delayed; the potential impact on the entity if the alliance is considered a change in the control of the business, including its debts and other material arrangements, and with respect to its tax characteristics; The company`s limited operating history and the fact that it has never produced a product; The company`s ability to achieve or maintain profitability in the future; The company`s dependence on the success of its leader, vibegron; The company`s dependence on its scientific, medical or key management staff and certain related companies to provide certain services to the company; clinical trial risks, including uncertainties related to the success of the company`s clinical trials for Vibegron and URO-902, as well as future candidates for treatment or products; uncertainties related to the regulatory landscape that governs gene therapy products; The company`s dependence on Merck Sharp – Dohme Corp.